Liquid medicine for conditioning breast diseases and preparation method thereof

Abstract

The invention discloses a liquid medicine for conditioning breast diseases. The liquid medicine comprises the following raw materials by weight: 12-22 g of garden burnet; 15 to 25 g of prunella vulgaris; 17 to 27g of seaweed; and 14-24g of fructus liquidambaris. The raw materials of the medicine liquid for conditioning breast diseases are medicinal and edible or traditional Chinese medicinal materials, so that the medicine liquid is small in side effect and suitable for long-term conditioning; the traditional Chinese medicine composition has a direct treatment effect on hyperplasia of mammary glands and breast distending pain before menstruation, and can be used as a mild auxiliary conditioning means for more serious mammary gland diseases.

Description

Technical Field

[0001] This invention relates to the field of traditional Chinese medicine preparation technology, specifically to a medicinal liquid for treating breast diseases and its preparation method. Background Technology

[0002] Breast hyperplasia and premenstrual breast tenderness are common and frequently occurring diseases among women. Modern medicine often uses hormone therapy or surgery, which have drawbacks such as significant side effects or high recurrence rates. Breast cancer is an even more serious threat to women's health, and patients urgently need safe and effective adjunctive treatments in addition to conventional therapies.

[0003] Traditional Chinese medicine (TCM) has unique advantages in treating breast diseases, often focusing on soothing the liver and regulating qi, promoting blood circulation and removing blood stasis, and softening and dispersing lumps. While some TCM compound formulas exist, some have complex formulations, significant side effects, and uncertain efficacy, with minimal results. Summary of the Invention

[0004] To address the aforementioned technical shortcomings, the purpose of this invention is to provide a medicinal liquid for treating breast diseases and its preparation method, which has a good effect on breast hyperplasia and premenstrual breast tenderness.

[0005] To solve the above-mentioned technical problems, the present invention adopts the following technical solution: The present invention provides a medicinal liquid for treating breast diseases, comprising the following raw materials in parts by weight: 12-22 grams of Sanguisorba officinalis; 15-25 grams of Prunella vulgaris; 17-27 grams of Sargassum fusiforme; and 14-24 grams of Liquidambar formosana.

[0006] Preferably, the raw materials include the following parts by weight: 17g of Sanguisorba officinalis, 20g of Prunella vulgaris, 22g of Sargassum fusiforme, and 19g of Liquidambar formosana.

[0007] The present invention provides a method for preparing a medicinal liquid for treating breast diseases, comprising the following steps: (1) decoction: weighing Sanguisorba officinalis, Prunella vulgaris, Sargassum fusiforme and Liquidambar formosana according to the weight parts, mixing them, soaking them in water, then decocting them, filtering them to obtain the medicinal liquid; (2) pulping: weighing figs and adding them to the medicinal liquid obtained in step (1), and pulping them together to obtain a uniform slurry composition.

[0008] Preferably, the figs are fresh figs or dried figs; when using fresh figs, the amount is 1-3 kg; when using dried figs, the amount is 300-900 g.

[0009] Preferably, in step (1), the amount of water added is 8-12 times the total weight of the raw materials.

[0010] Preferably, in step (1), the soaking time is 30-60 minutes.

[0011] Preferably, in step (1), the clay pot is boiled twice. After boiling over high heat for the first time, it is boiled for 40-60 minutes. The second boiling time is 10-40 minutes. The filtrates obtained from the two boilings are combined.

[0012] The beneficial effects of this invention are as follows: the formula is scientifically formulated. In this formula, Sanguisorba officinalis cools the blood and detoxifies, Prunella vulgaris clears liver fire and disperses stagnation, Sargassum softens hardness and disperses nodules, Liquidambar formosana promotes blood circulation and diuresis, and Fig tree moistens the lungs and strengthens the spleen. The combined effects of these herbs are to soothe the liver and relieve stagnation, promote blood circulation and unblock the meridians, and resolve phlegm and disperse nodules, thus addressing the main pathogenesis of breast diseases.

[0013] The medicinal liquid for treating breast diseases provided by this invention uses medicinal and edible materials or traditional Chinese medicinal herbs as raw materials. It has few side effects and is suitable for long-term use. It has a direct therapeutic effect on breast hyperplasia and premenstrual breast tenderness. For more serious breast diseases, it can be used as a mild auxiliary treatment method. Detailed Implementation

[0014] The technical solutions of the present invention will be clearly and completely described below with reference to the embodiments of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative effort are within the scope of protection of the present invention.

[0015] Example 1:

[0016] Weigh out 17g of Sanguisorba officinalis, 20g of Prunella vulgaris, 22g of Sargassum fusiforme, and 19g of Liquidambar formosana. Place the above four herbs in a decoction pot, add 800ml of drinking water, and soak for 40 minutes; bring to a boil over high heat, then simmer over low heat for 50 minutes, filter with gauze to obtain the first decoction; add another 600ml of water to the dregs, continue to simmer over low heat for 30 minutes, and filter to obtain the second decoction; combine the two decoctions to obtain approximately 1 liter of liquid.

[0017] Weigh 200 grams of fresh figs and add them to the above 1 liter of medicinal liquid. Use a high-speed homogenizer to homogenize the mixture until a uniform slurry is formed, thus obtaining the composition of the present invention. It can be packaged and stored at 4°C.

[0018] Example 2:

[0019] Weigh out 15g of Sanguisorba officinalis, 23g of Prunella vulgaris, 20g of Sargassum fusiforme, and 17g of Liquidambar formosana. Prepare the liquid using the same method as in Example 1, yielding approximately 0.9 liters of liquid. Weigh out 45g of dried figs, add them to the liquid, and mix thoroughly.

[0020] Comparative Example 1:

[0021] Weigh out 20 grams of Prunella vulgaris, 22 grams of Sargassum fusiforme, and 19 grams of Liquidambar formosana, without adding Sanguisorba officinalis. The preparation method is the same as in Example 1, with the water volume remaining unchanged. Finally, use the medicinal solution to pulp 200 grams of fresh figs to obtain the comparative product.

[0022] Comparative Example 2:

[0023] Weigh out 17g of Sanguisorba officinalis, 20g of Prunella vulgaris, 22g of Laminaria japonica (replacing seaweed), and 19g of Liquidambar formosana. The preparation method is the same as in Example 1. Use the medicinal solution to pulp 200g of fresh figs to obtain the comparative product.

[0024] Experimental example: The therapeutic effect on a rat model of mammary hyperplasia. To objectively evaluate the efficacy of the present invention, animal experiments were conducted.

[0025] Laboratory animals and modeling:

[0026] 1. Fifty healthy, non-pregnant female SD rats, weighing 180-220g, were randomly divided into 5 groups of 10 rats each. These groups were: blank control group, model group, Example 1 group, Comparative Example 1 group, and Comparative Example 2 group.

[0027] Except for the blank control group which was injected with an equal volume of physiological saline, the other four groups of rats were induced to develop a mammary hyperplasia model by regularly injecting estradiol benzoate (0.3 mg / kg) and progesterone (4 mg / kg) into their muscles 15 times.

[0028] 2. Drug administration intervention:

[0029] After successful modeling, the medication was administered via gavage once daily for 30 consecutive days.

[0030] Blank control group and model group: administered equal volume of physiological saline by gavage;

[0031] Example 1 group: The slurry prepared in Example 1 was administered by gavage at a rate of 10 mL / kg (based on slurry);

[0032] Comparative Example 1: The comparative product prepared by gavage in Comparative Example 1 was administered at the same dosage as in Example 1.

[0033] Comparative Example 2: The comparative product prepared by gavage in Comparative Example 2 was administered at the same dosage as in Example 1.

[0034] 3. Evaluation indicators and results: After the last administration, the mammary diameter and nipple height of rats in each group were measured. The data are expressed as mean ± standard deviation. The results are shown in Table 1.

[0035] Table 1 Comparison of mammary hyperplasia-related indicators in different groups of rats (x±s, n=10).

[0036] Group Breast diameter (mm) Nipple height (mm) Blank control group 1.05±0.11 1.28±0.19 Model group 1.92±0.15△△ 2.31±0.38△△ Example 1 Group 1.15±0.16** 1.41±0.22** Comparative Example 1 1.68±0.21# 1.95±0.35# Comparative Example 2 1.59±0.18# 1.87±0.29#

[0037] Table 1

[0038] Note: Compared with the blank control group, △△P<0.01; compared with the model group, **P<0.01; compared with Example 1 group, #P<0.05.

[0039] 4. Experimental conclusions:

[0040] Compared with the blank control group, the breast diameter and nipple height of the model group were significantly increased (P<0.01), indicating that the breast hyperplasia model was successfully replicated.

[0041] Compared with the model group, both indicators in Example 1 group were significantly reduced (P<0.01), indicating that the composition of the present invention can effectively inhibit breast hyperplasia and eliminate swelling.

[0042] Although Comparative Example 1 (without Sanguisorba officinalis) and Comparative Example 2 (with seaweed replaced by kelp) showed some improvement compared to the model group, their effects were significantly worse than those of Example 1 (P<0.05). This demonstrates that the specific formulation of this invention (the combination of Sanguisorba officinalis and seaweed) has a synergistic effect, and the superior effect cannot be achieved by simply piling up or arbitrarily replacing drugs.

[0043] Safety observation: During the experiment, the rats in each drug administration group showed normal behavior, activity, feeding and excretion, and there were no signs of poisoning or death, indicating that the composition of the present invention has good safety.

[0044] Clinical efficacy observation:

[0045] To verify the efficacy of this invention in human applications, a preliminary clinical observation was conducted. One hundred patients meeting the diagnostic criteria for breast hyperplasia with premenstrual breast tenderness were randomly divided into an experimental group and a control group, with 50 patients in each group. The experimental group took the composition prepared in Example 1 of this invention, 150 mL twice daily; the control group took commercially available breast pain relief tablets. One month constituted one course of treatment, and three consecutive courses were observed.

[0046] Results: The total effective rate in the experimental group was 94% (20 cases cured, 18 cases showing significant improvement, 9 cases showing improvement, and 3 cases showing no effect), while the total effective rate in the control group was 78%. The experimental group was significantly superior to the control group in relieving pain and shrinking lumps, and no significant adverse reactions were reported. This indicates that the composition of the present invention is safe and effective in clinical applications.

[0047] Obviously, those skilled in the art can make various modifications and variations to this invention without departing from its spirit and scope. Therefore, if these modifications and variations fall within the scope of the claims of this invention and their equivalents, this invention also intends to include these modifications and variations.

Claims

1. A medicinal liquid for treating breast diseases, characterized in that, The ingredients include the following parts by weight: 12-22 grams of Sanguisorba officinalis; 15-25 grams of Prunella vulgaris; 17-27 grams of Sargassum fusiforme; and 14-24 grams of Liquidambar formosana.

2. The medicinal liquid for treating breast diseases as described in claim 1, characterized in that, The ingredients include the following parts by weight: 17g of Sanguisorba officinalis, 20g of Prunella vulgaris, 22g of Sargassum fusiforme, and 19g of Liquidambar formosana.

3. The method for preparing a medicinal solution for treating breast diseases as described in claim 1, characterized in that, Includes the following steps: (1) Decoction: Weigh out the following ingredients according to the stated weight proportions: Sanguisorba officinalis, Prunella vulgaris, Sargassum fusiforme, and Liquidambar formosana. Mix them together, soak them in water, then decoct them and filter to obtain the medicinal liquid. (2) Pulping: Weigh out figs and add them to the medicinal liquid obtained in step (1), and pulverize them together to obtain a uniform slurry composition.

4. The method for preparing a medicinal liquid for treating breast diseases as described in claim 3, characterized in that, The figs mentioned are fresh figs or dried figs; when using fresh figs, the amount is 1-3 kg; when using dried figs, the amount is 300-900 g.

5. The method for preparing a medicinal solution for treating breast diseases as described in claim 3, characterized in that, In step (1), the amount of water added is 8-12 times the total weight of the raw materials.

6. The method for preparing a medicinal liquid for treating breast diseases as described in claim 3, characterized in that, In step (1), the soaking time is 30-60 minutes.

7. The method for preparing a medicinal solution for treating breast diseases as described in claim 3, characterized in that, In step (1), the clay pot is boiled twice. After boiling over high heat for the first time, it is boiled for 40-60 minutes. The second boiling time is 10-40 minutes. The filtrates obtained from the two boilings are combined.